Browse News

Found 109 articles

• Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals

  5/25/2023

  Adamis Pharmaceuticals Corporation, a commercial-stage biopharmaceutical company, announced the closing of its merger with DMK Pharmaceuticals Corporation.

• Adamis Pharmaceuticals Announces Reverse Stock Split - May 19, 2023

  5/19/2023

  Adamis Pharmaceuticals Corporation, a commercial-stage biopharmaceutical company, announced that it will effect a 1-for-70 reverse stock split of its common stock that will become effective on May 22, 2023, at 12:01 a.m., Eastern Time.

• Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

  5/15/2023

  Adamis Pharmaceuticals Corporation announced financial results for the first quarter ended March 31, 2023, and provided an update on recent corporate developments.

• Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update

  5/8/2023

  Adamis Pharmaceuticals announced that it will host an investor conference call on Monday, May 15, 2023 at 2:00 pm PT to discuss its financial and operating results for the first quarter 2023 as well as provide a corporate update, which may include an update concerning the results of the company’s special meeting of stockholders scheduled to be held on May 15, 2023 at 10:00 am PT as well as the proposals to be considered and acted upon at the meeting.

• Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update

  3/16/2023

  Adamis Pharmaceuticals Corporation announced financial results for the full year ended December 31, 2022, and provided an update on recent corporate developments.

• Adamis Pharmaceuticals Announces $3.0 Million Registered Direct Offering

  3/14/2023

  Adamis Pharmaceuticals Corporation announced it has entered into a securities purchase agreement with a single, healthcare-focused institutional investor for the purchase and sale of 16,500,000 shares of its common stock and pre-funded warrants to purchase up to 7,500,000 shares of common stock, together with warrants to purchase up to 48,000,000 shares of common stock, at a combined purchase price of $0.125 per share and accompanying warrants, pursuant to a registered direct offering.

• Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update

  3/14/2023

  Adamis Pharmaceuticals Corporation announced that it will host an investor conference call on Thursday, March 16, 2023 at 2:00 p.m. PT to discuss its financial and operating results for the fourth quarter and full year 2022 as well as provide a corporate update.

• Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger

  2/27/2023

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) and DMK Pharmaceuticals, Corp. today announced that the companies have entered into an Agreement and Plan of Merger and Reorganization (the “Agreement”).

• Nasdaq Grants Adamis Pharmaceuticals’ Request for Extension to Comply with Continued Listing Requirements

  2/22/2023

  Adamis Pharmaceuticals Corporation announced that the Nasdaq Hearings Panel has granted the Company’s request for continued listing on Nasdaq, pursuant to an extension through June 26, 2023 to evidence compliance with the $1.00 bid price requirement and its continued compliance with all other applicable criteria for continued listing on the Nasdaq Capital Market.

• Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

  11/14/2022

  Adamis Pharmaceuticals Corporation reported financial results for the third quarter of 2022 and provided an update on recent corporate developments.

• Adamis Pharmaceuticals Schedules Third Quarter 2022 Financial Results Conference Call and Corporate Update

  11/7/2022

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it will host an investor conference call on Monday, November 14, 2022 at 2:00 p.m. PT to discuss its financial and operating results for the third quarter 2022 as well as provide a corporate update.

• Adamis Announces Review of Strategic Alternatives

  10/3/2022

  Adamis Pharmaceuticals Corporation announced that following the recently announced halting of the Company’s Phase 2/3 clinical trial examining the effects of Tempol in high risk subjects with early COVID-19 infection, it has initiated a process to explore a range of strategic and financing alternatives focused on maximizing stockholder value.

• Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects

  9/21/2022

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the third planned interim analysis of the Phase 2/3 clinical trial examining the effects of Tempol in high risk subjects with early COVID-19 infection.

• Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects

  9/12/2022

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19 has reached the initial planned enrollment of 248 subjects.

• High-Dose Naloxone Product Giving People Hope to Help Combat Growing Opioid Overdose Trend

  8/31/2022

  On International Overdose Awareness Day, community encouraged to learn about additional treatment options to help save lives.

• Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders

  8/12/2022

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its 2022 Annual Meeting of Stockholders (“Annual Meeting”) was convened, as scheduled.

• Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

  8/10/2022

  Adamis Pharmaceuticals Corporation reported financial results for the second quarter of 2022 and provided an update on recent corporate developments.

• Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update

  8/8/2022

  Adamis Pharmaceuticals Corporation today announced that it will host an investor conference call on Wednesday, August 10, 2022 at 1:30 p.m. Pacific Time to discuss its financial and operating results for the second quarter 2022 as well as provide a corporate update.

• Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19Interim DSMB review expected in late September

  7/29/2022

  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19.

• Leading Independent Proxy Advisory Firm ISS Recommends Adamis Pharmaceuticals’ Stockholders Vote FOR Critical Proposals at Upcoming Annual Meeting

  7/29/2022

  Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that Institutional Shareholder Services Inc. ("ISS"), a leading independent proxy advisory firm, has recommended the Company’s stockholders vote FOR Proposal #2 and Proposal #3 on the agenda at the upcoming Annual Meeting of Stockholders (the “Annual Meeting”) on August 12, 2022.